Radiotherapy Treatments for Neoplasms of the Limbs
1 other identifier
observational
3,000
1 country
1
Brief Summary
In this observational study patients treated at European Institute of Oncology with radiotherapy to limbs will be included
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 22, 2018
CompletedFirst Submitted
Initial submission to the registry
March 22, 2024
CompletedFirst Posted
Study publicly available on registry
March 28, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2025
CompletedAugust 28, 2025
August 1, 2025
7.9 years
March 22, 2024
August 22, 2025
Conditions
Outcome Measures
Primary Outcomes (2)
Overall survival
Number of patients death
5 years
Disease free survival
Number of oncological event (local recurrence, distant metastasis, other primary tumor)
5 years
Study Arms (1)
Radiotherapy to limbs
Collection of data of patients receiving RT to limbs
Eligibility Criteria
Patients treated at European Institute of Oncology with radiotherapy to limbs
You may qualify if:
- Patients treated with radiotherapy for curative, palliative, neo-adjuvant, and adjuvant purposes in the upper and lower limbs for:
- Primary bone tumors, Primary soft tissue tumors, Primary tumors of the cardio-circulatory system, Primary tumors of the lymphatic system, Primary tumors of the nervous system and skin, Secondary metastases from various origins localized in that district.
- Signed informed consent
You may not qualify if:
- \. Radiotherapy in districts other than limbs.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
European Institute of Oncology
Milan, Italy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Barbara Alicja Jereczek
European Institute of Oncology
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 22, 2024
First Posted
March 28, 2024
Study Start
February 22, 2018
Primary Completion
December 31, 2025
Study Completion
December 31, 2025
Last Updated
August 28, 2025
Record last verified: 2025-08